Using blood flow imaging to assess glaucoma
Ocular Blood Flow Imaging for Glaucoma Assessment
NA · University of Maryland, Baltimore · NCT05726058
This study is testing whether new imaging tools can help doctors see differences in blood flow in the eyes of people with glaucoma compared to healthy individuals.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 18 Years to 88 Years |
| Sex | All |
| Sponsor | University of Maryland, Baltimore (other) |
| Locations | 1 site (Baltimore, Maryland) |
| Trial ID | NCT05726058 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of the XyCAM RI and XyCAM FC, FDA-cleared retinal blood flow imaging instruments, in managing glaucoma. The study aims to determine if blood flow measurements can differentiate between early-stage glaucoma and matched controls, while also validating the simultaneous capture of stereo fundus photography and ocular blood flow monitoring. Participants will undergo a series of imaging tests, including blood flow imaging and standard clinical assessments, to gather comprehensive data on their ocular health. The trial will involve both healthy controls and patients diagnosed with moderate to severe glaucoma.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 18 and older with binocular vision, either healthy controls or those recommended for glaucoma assessment or diagnosed with moderate to severe glaucoma.
Not a fit: Patients with significant media opacity, previous ocular surgeries (other than uncomplicated cataract extraction), or other ocular diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the accuracy of glaucoma assessments and improve patient management strategies.
How similar studies have performed: Other studies utilizing advanced imaging techniques for glaucoma assessment have shown promise, indicating potential success for this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 and older with binocular vision * Able to provide informed consent * Patient is a healthy control OR is recommended for glaucoma assessment OR diagnosed with moderate to severe glaucoma in at least one eye as determined by Hodapp Anderson Criteria Exclusion Criteria: * The subject has significant media opacity (e.g., a visually significant cataract or significant corneal scar) * The subject has previous ocular surgery other than uncomplicated cataract extraction, laser trabeculoplasty (ALT or SLT), or YAG capsulotomy * The subject has prior ocular disease other than glaucoma * The subject has anatomically narrow angles or a prior adverse reaction to administration of Tropicamide or fluorescein dye * The subject has more than 15 diopters of refractive error * The subject is a female who is pregnant or nursing * The subject has diabetes mellitus
Where this trial is running
Baltimore, Maryland
- University of Maryland Eye Associates at Redwood — Baltimore, Maryland, United States (RECRUITING)
Study contacts
- Study coordinator: Osamah J Saeedi, MD, MS
- Email: osaeedi@som.umaryland.edu
- Phone: (410) 328-5929
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Glaucoma, glaucoma, xycam, blood flow, imaging, ophthalmology, retinal blood flow, eye disease